Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

BEACON-AA: Apixaban med eller uten klopidogrel hos pasienter med hjerneslag og atrieflimmer samt cerebral aterosklerose

15. november 2026 oppdatert av: Yonsei University

En multikenter prospektiv randomisert studie for å evaluere effekten av apixaban og klopidogrel på forebygging av tilbakevendende iskemisk slag hos pasienter med atrieflimmer og cerebral aterosklerose

This trial aims to compare the safety and efficacy of apixaban alone versus apixaban combined with clopidogrel in patients with acute ischemic stroke associated with non-valvular atrial fibrillation and concomitant symptomatic intracranial or extracranial atherosclerosis or complex plaque in the ascending aorta or aortic arch (≥4 mm in thickness, mobile, or ulcerated). Participants will be randomly assigned in a 1:1 ratio to receive apixaban monotherapy or dual therapy with clopidogrel for 30 days. The primary outcome is the incidence of new symptomatic or asymptomatic ischemic lesions on DWI/FLAIR at 30 (±5) days compared with baseline MRI, adjudicated by a central committee.

Studieoversikt

Detaljert beskrivelse

Although oral anticoagulants are effective in preventing cardioembolic stroke in patients with non-valvular atrial fibrillation (NVAF), a considerable proportion of ischemic strokes in these patients are caused by concomitant large artery atherosclerosis. Carotid or intracranial artery stenosis is present in a substantial number of patients with NVAF and is associated with a higher risk of recurrent cerebral infarction despite standard anticoagulation. In such patients, adding an antiplatelet agent to oral anticoagulation may theoretically reduce atherothrombotic events, but it also raises concern for increased bleeding risk. Recent clinical evidence on this issue remains limited, and the optimal antithrombotic strategy for patients with NVAF and coexisting symptomatic atherosclerotic stenosis has not been clearly established.

The BEACON-AA trial is a multicenter, randomized, open-label, blinded-endpoint (PROBE) study designed to compare the safety and efficacy of apixaban monotherapy versus apixaban combined with clopidogrel in patients with acute ischemic stroke associated with non-valvular atrial fibrillation (NVAF) and concomitant symptomatic intracranial or extracranial atherosclerosis or complex plaque in the ascending aorta or aortic arch (≥4 mm in thickness, mobile, or ulcerated). Participants will be randomized in a 1:1 ratio to receive apixaban alone or apixaban plus clopidogrel for 30 days, followed by apixaban monotherapy thereafter.

Brain MRI including diffusion-weighted and FLAIR sequences will be performed at baseline and at 30 ± 5 days to assess new or recurrent ischemic lesions. The primary efficacy outcome is the incidence of new symptomatic or asymptomatic ischemic lesions on DWI/FLAIR at 30(±5) days compared with baseline MRI, adjudicated by a central committee. Secondary efficacy outcomes include: 1) incidence of symptomatic ischemic stroke or transient ischemic attack within 90 days, 2) incidence of acute coronary syndrome within 90 days,3) cardiovascular mortality within 90 days, 4) composite major cardiovascular events within 90 days, 5) all-cause mortality within 90 days, 6) proportion of patients with modified Rankin Scale (mRS) 0-2 at 90 days, and 7) proportion of patients with mRS 0-3 at 90 days. The primary safety outcomes are: 1) incidence of major bleeding within 90 days, defined according to the International Society on Thrombosis and Haemostasis (ISTH) criteria and 2) incidence of new asymptomatic cerebral hemorrhages detected on brain MRI(MR-Diffusion/FLAIR/SWI (or GRE)) at 30 ± 5 days after randomization. All imaging and clinical events will be independently adjudicated by blinded central adjudication committees.

Studietype

Intervensjonell

Registrering (Antatt)

586

Fase

  • Fase 4

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Young Dae Kim, M.D. Ph.D.
  • Telefonnummer: 02-2228-1619
  • E-post: NEURO05@YUHS.AC

Studiesteder

      • Busan, Sør -Korea
        • Rekruttering
        • Pusan National University Hospital
        • Ta kontakt med:
      • Busan, Sør -Korea
        • Rekruttering
        • Dong-A University Hospital
        • Ta kontakt med:
      • Chuncheon, Sør -Korea
        • Rekruttering
        • Hallym University Chuncheon Sacred Heart Hospital
        • Ta kontakt med:
      • Daegu, Sør -Korea
        • Rekruttering
        • Keimyung University Dongsan Hospital
        • Ta kontakt med:
      • Goyang, Sør -Korea
        • Rekruttering
        • National Health Insurance Service Ilsan Hospital
        • Ta kontakt med:
      • Incheon, Sør -Korea
        • Rekruttering
        • Inha University Hospital
        • Ta kontakt med:
      • Incheon, Sør -Korea
        • Rekruttering
        • Gachon University Gil Medical Center
        • Ta kontakt med:
      • Incheon, Sør -Korea
        • Rekruttering
        • Catholic Kwandong University International St. Mary's Hospital
        • Ta kontakt med:
      • Seoul, Sør -Korea
        • Rekruttering
        • Samsung Medical Center
        • Ta kontakt med:
      • Seoul, Sør -Korea
        • Rekruttering
        • Seoul National University Hospital
        • Ta kontakt med:
          • Keun-Hwa Jung, Professor
          • Telefonnummer: +82-1588-5700
          • E-post: jungkh@gmail.com
      • Seoul, Sør -Korea
        • Rekruttering
        • Korea University Anam Hospital
        • Ta kontakt med:
      • Seoul, Sør -Korea
        • Rekruttering
        • Kangbuk Samsung Hospital
        • Ta kontakt med:
      • Seoul, Sør -Korea
        • Rekruttering
        • Ewha Womans University Seoul Hospital
        • Ta kontakt med:
      • Seoul, Sør -Korea
        • Rekruttering
        • Gangnam Severance Hospital
        • Ta kontakt med:
          • Yo Han Jung, Professor
          • Telefonnummer: +82-1599-6114
          • E-post: YHJUNG@yuhs.ac
      • Seoul, Sør -Korea
        • Rekruttering
        • Hanyang University Seoul Hospital
        • Ta kontakt med:
      • Seoul, Sør -Korea
        • Rekruttering
        • Kyung Hee University Hospital
        • Ta kontakt med:
      • Seoul, Sør -Korea
        • Rekruttering
        • Kyung Hee University Hospital at Gangdong
        • Ta kontakt med:
      • Seoul, Sør -Korea
        • Rekruttering
        • Inje University Sanggye Paik Hospital
        • Ta kontakt med:
      • Seoul, Sør -Korea
        • Rekruttering
        • Kangdong Sacred Heart Hospital
        • Ta kontakt med:
      • Seoul, Sør -Korea
        • Rekruttering
        • Yonsei University College of Medicine
        • Ta kontakt med:
          • Young Dae Kim, Professor
          • Telefonnummer: +82-2-2228-1619
          • E-post: NEURO05@YUHS.AC
      • Yŏngin, Sør -Korea
        • Rekruttering
        • Yongin Severance Hospital
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

19 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Adults aged 19 years or older at the time of enrollment.

  2. Patients with non-valvular atrial fibrillation (NVAF) documented by electrocardiography.

  3. Acute ischemic stroke confirmed by brain MRI (diffusion-weighted and FLAIR sequences), with last known well within 120 hours prior to randomization.

  4. Presence of clinically significant atherosclerosis in the cerebral or aortic arteries, meeting at least one of the following criteria:

    ① ≥30% stenosis in the relevant artery (the artery supplying the infarcted territory) demonstrated by CTA, MRA, or DSA - using the WASID criteria for intracranial arteries and NASCET criteria for extracranial arteries.

    ② High-risk atherosclerotic plaque features in the relevant artery demonstrated by CTA, MRA, or ultrasound, such as ulceration, intraplaque hemorrhage, mobile plaque, or a large lipid core (involving ≥25% of plaque cross-sectional area) on CTA/MRA, or ulceration, mobile plaque, or hypoechoic/echolucent plaque on ultrasound; or presence of branch artery occlusive disease (BAOD).

    ③ Complex aortic plaque (≥4 mm in thickness, mobile, or ulcerative) identified in the ascending aorta or aortic arch by transthoracic/transesophageal echocardiography or coronary CT angiography.

  5. Written informed consent provided by the participant or a legally authorized representative.

Exclusion Criteria:

  1. Presence of mechanical heart valves or rheumatic mitral stenosis.
  2. Requirement for antithrombotic agents other than apixaban and clopidogrel.
  3. Planned percutaneous coronary intervention, coronary artery bypass graft surgery, carotid endarterectomy, or intracranial stenting within 3 months after enrollment.
  4. Presence of mural thrombus in the heart confirmed by imaging.
  5. Renal impairment with creatinine clearance ≤25 mL/min.
  6. Severe hepatic impairment, including acute hepatitis, chronic active hepatitis, hepatic lesions or coagulopathy, hepatic failure, or laboratory evidence of AST/ALT >2× the upper limit of normal (ULN) or total bilirubin ≥1.5× ULN.
  7. Small-vessel occlusion (lacunar infarction) according to the TOAST classification.
  8. History within the past 30 days of gastrointestinal bleeding, vascular malformation of the brain or spinal cord, recent brain, spinal, or ophthalmologic surgery or trauma, esophageal varices, or intracranial hemorrhage at any time; or chronic regular use of NSAIDs (≥3 days per week for ≥2 consecutive weeks).
  9. Ischemic stroke occurring despite concurrent use of both NOAC and antiplatelet therapy.
  10. Planned surgery or high-bleeding-risk procedure within 3 months, or presence of active bleeding at enrollment.
  11. Anemia (hemoglobin < 8.0 g/dL) or thrombocytopenia (platelet count < 100,000/µL).
  12. Pre-stroke modified Rankin Scale (mRS) ≥ 2.
  13. Severe comorbid illness or malignancy not in complete remission with an expected life expectancy <1 year.
  14. Known hypersensitivity or allergy to apixaban or clopidogrel.
  15. Pregnant or breastfeeding women.
  16. Uncontrolled diabetes mellitus (HbA1c > 10.0%) or severe hypertension (systolic ≥ 220 mmHg or diastolic ≥ 120 mmHg).
  17. Concomitant use of strong CYP3A4 and P-glycoprotein inhibitors that can significantly increase apixaban exposure (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin).
  18. Concomitant use of strong CYP2C19 inducers that can enhance clopidogrel antiplatelet effect and increase bleeding risk (e.g., rifampin, carbamazepine, phenytoin, phenobarbital, St. John's wort).
  19. Clinically significant mass effect due to space-occupying cerebral infarction, or patients expected to require decompressive craniectomy, including those with midline shift > 5 mm, loss of basal cisterns, herniation, fourth-ventricle compression, or obstructive hydrocephalus in posterior fossa infarcts.
  20. Intracranial hemorrhage or hemorrhagic transformation (PH1 or PH2) according to ECASS criteria.
  21. Participation in another interventional clinical trial within the past 30 days or concurrent participation in another interventional study (non-interventional observational or registry studies may be allowed at the investigator's discretion).
  22. Any other condition that, in the investigator's judgment, would make participation or continued involvement in the study inappropriate or infeasible.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Apixaban and Clopidogrel Combination Therapy

Participants receive apixaban(5mg twice daily, or 2.5mg twice daily if indicated) plus clopidogrel 75mg daily for 30days, followed by apixaban monotherapy thereafter.

Apixaban 5mg(or 2.5mg if indicated) twice daily. Used as monotherapy or in combination with clopidogrel for 30 days, then continued as monotherapy.

Andre navn:
  • Eliquis

Clopidogrel 75mg once daily for 30 days in combination with apixaban, then discontinued.

Andre navn:
  • Plavix
Aktiv komparator: Apixaban Monotherapy

Participants receive apixaban 5mg(or 2.5mg if indicated) twice daily as monotherapy for 30 days and continue apixaban monotherapy thereafter.

Apixaban 5mg(or 2.5mg if indicated) twice daily. Used as monotherapy or in combination with clopidogrel for 30 days, then continued as monotherapy.

Andre navn:
  • Eliquis

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of new symptomatic or asymptomatic ischemic lesions on DWI/FLAIR at 30(±5) days compared with baseline MRI, adjudicated by a central committee
Tidsramme: At 30 ± 5 days after randomization

New ischemic lesions, either symptomatic or asymptomatic, identified on DWI/FLAIR at 30 (±5) days compared with baseline MRI, as adjudicated by a central adjudication committee.

At 30 ± 5 days after randomization

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of symptomatic ischemic stroke or transient ischemic attack (TIA)
Tidsramme: Within 90 days after randomization

Occurrence of new symptomatic ischemic stroke or transient ischemic attack confirmed by clinical and/or imaging criteria.

Within 90 days after randomization
Incidence of acute coronary syndrome (ACS)
Tidsramme: Within 90 days after randomization

Occurrence of acute coronary syndrome, including unstable angina or myocardial infarction, confirmed by standard diagnostic criteria.

Within 90 days after randomization
Cardiovascular mortality
Tidsramme: Within 90 days after randomization

Death due to fatal stroke, fatal myocardial infarction, or sudden death not clearly attributed to non-vascular causes.

Within 90 days after randomization
Composite major cardiovascular events
Tidsramme: Within 90 days after randomization

Composite of recurrent stroke (ischemic or hemorrhagic), acute coronary syndrome, or cardiovascular death.

Within 90 days after randomization
All-cause mortality
Tidsramme: Within 90 days after randomization

Death from any cause during the 90-day follow-up period.

Within 90 days after randomization
Proportion of patients with modified Rankin Scale (mRS) score 0-2
Tidsramme: At 90 days after randomization

Functional independence defined as mRS score of 0-2 at day 90.

At 90 days after randomization
Proportion of patients with modified Rankin Scale (mRS) score 0-3
Tidsramme: At 90 days after randomization

Favorable functional outcome defined as mRS score of 0-3 at day 90.

At 90 days after randomization
Incidence of major bleeding events according to the ISTH criteria
Tidsramme: Within 90 days after randomization

Major bleeding events defined by the International Society on Thrombosis and Haemostasis (ISTH) criteria, including fatal bleeding, symptomatic intracranial hemorrhage, intraocular bleeding causing vision loss, bleeding resulting in inability to perform usual activities, bleeding requiring transfusion of ≥2 units of whole blood or red cells, or bleeding leading to hospitalization.

Within 90 days after randomization
Incidence of new asymptomatic cerebral hemorrhages detected on brain MRI(MR-Diffusion/FLAIR/SWI (or GRE))
Tidsramme: At 30 ± 5 days after randomization

Newly developed asymptomatic cerebral hemorrhages identified on MR-Diffusion/FLAIR/SWI(or GRE) performed 30 ± 5 days after randomization.

At 30 ± 5 days after randomization

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

14. juli 2026

Primær fullføring (Antatt)

1. juli 2029

Studiet fullført (Antatt)

31. august 2029

Datoer for studieregistrering

Først innsendt

14. november 2025

Først innsendt som oppfylte QC-kriteriene

14. november 2025

Først lagt ut (Faktiske)

19. november 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

15. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere